MXPA04003674A - Uso mejorado de compuesto antitumoral en terapia de cancer. - Google Patents

Uso mejorado de compuesto antitumoral en terapia de cancer.

Info

Publication number
MXPA04003674A
MXPA04003674A MXPA04003674A MXPA04003674A MXPA04003674A MX PA04003674 A MXPA04003674 A MX PA04003674A MX PA04003674 A MXPA04003674 A MX PA04003674A MX PA04003674 A MXPA04003674 A MX PA04003674A MX PA04003674 A MXPA04003674 A MX PA04003674A
Authority
MX
Mexico
Prior art keywords
cancer therapy
improved use
antitumoral compound
antitumoral
compound
Prior art date
Application number
MXPA04003674A
Other languages
English (en)
Inventor
Hidalgo Manuel
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MXPA04003674A publication Critical patent/MXPA04003674A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se dan programas de dosificacion mejorados para ecteinascidin 743 para el tratamiento de cancer.
MXPA04003674A 2001-10-19 2002-10-21 Uso mejorado de compuesto antitumoral en terapia de cancer. MXPA04003674A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34841401P 2001-10-19 2001-10-19
PCT/US2002/033548 WO2003039571A1 (en) 2001-10-19 2002-10-21 Improved use of antitumoral compound in cancer therapy

Publications (1)

Publication Number Publication Date
MXPA04003674A true MXPA04003674A (es) 2004-07-23

Family

ID=23367939

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003674A MXPA04003674A (es) 2001-10-19 2002-10-21 Uso mejorado de compuesto antitumoral en terapia de cancer.

Country Status (15)

Country Link
US (1) US20050004018A1 (es)
EP (1) EP1435988A4 (es)
JP (1) JP2005509650A (es)
KR (1) KR20050038578A (es)
CN (1) CN1606449A (es)
AU (1) AU2002343548B2 (es)
BR (1) BR0213424A (es)
CA (1) CA2462502A1 (es)
HU (1) HUP0401903A3 (es)
IL (1) IL161430A0 (es)
MX (1) MXPA04003674A (es)
NO (1) NO20042035L (es)
PL (1) PL368458A1 (es)
RU (1) RU2306933C2 (es)
WO (1) WO2003039571A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
DK1365808T3 (da) * 2000-11-06 2011-05-16 Pharma Mar Sa Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
WO2005049031A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Combination
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
US20080293725A1 (en) * 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
RU2359700C2 (ru) * 2004-10-26 2009-06-27 Фарма Мар С.А., Сосьедад Униперсональ Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
WO2006046079A1 (en) 2004-10-29 2006-05-04 Pharma Mar S.A., Sociedad Unipersonal Formulations comprising ecteinascidin and a disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2007134203A2 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
EP2129396B1 (en) 2007-02-16 2013-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
UA104868C2 (uk) * 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
PL2544680T3 (pl) 2010-03-11 2015-08-31 Merrimack Pharmaceuticals Inc Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego
CN108114285A (zh) 2011-07-15 2018-06-05 纽斯尔特科学公司 用于调节代谢途径的组合物和方法
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
WO2014078459A1 (en) 2012-11-13 2014-05-22 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
PT1280809E (pt) * 2000-04-12 2005-11-30 Pharma Mar Sa Derivados antitumorais de ecteinascidina
DK1365808T3 (da) * 2000-11-06 2011-05-16 Pharma Mar Sa Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2006046079A1 (en) * 2004-10-29 2006-05-04 Pharma Mar S.A., Sociedad Unipersonal Formulations comprising ecteinascidin and a disaccharide

Also Published As

Publication number Publication date
HUP0401903A3 (en) 2008-07-28
AU2002343548B8 (en) 2003-05-19
IL161430A0 (en) 2004-09-27
CA2462502A1 (en) 2003-05-15
JP2005509650A (ja) 2005-04-14
BR0213424A (pt) 2004-12-14
WO2003039571A1 (en) 2003-05-15
CN1606449A (zh) 2005-04-13
HUP0401903A2 (hu) 2005-01-28
KR20050038578A (ko) 2005-04-27
PL368458A1 (en) 2005-03-21
EP1435988A1 (en) 2004-07-14
RU2306933C2 (ru) 2007-09-27
EP1435988A4 (en) 2008-01-09
RU2004115110A (ru) 2005-03-10
AU2002343548B2 (en) 2007-11-08
NO20042035L (no) 2004-05-18
US20050004018A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
MY136520A (en) Novel compounds
TW200626526A (en) Pharmaceutical compositions for the treatment of neoplasms
IL164599A0 (en) Combination therapy for the treatment of cancer
AP2000001785A0 (en) Medicaments
PL354540A1 (en) Drugs for the treatment of malignant tumours
EP1446012A4 (en) Bacteriolytic combination therapy for the treatment of tumors
DE69905170D1 (en) Thiazolopyrimidinderivate
PL356846A1 (en) Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
HK1060067A1 (en) Compositions for antitumour treatment containing ecteinascidin 743
HK1072443A1 (en) Immunoconjugates for the treatment of tumours
HUP0500424A3 (en) Combination therapy for the treatment of cancer
HK1040983A1 (en) Quinones for treatment of diseases.
YU13301A (sh) Muskarinski agonisti i antagonisti
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
MXPA04004306A (es) Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
HK1043058A1 (zh) 異環磷酰胺芥子類似物及其用途
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
LT1496918T (lt) Natrio meta-arsenito naudojimas navikams gydyti
EP1303520A4 (en) THERAPEUTIC COMPOUNDS AND METHODS
IL139144A0 (en) Mycobacterial inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal